Research have indicated that lycopene treatment can selectively inhibit cell division cycle by downregulating biomarkers of tumour promotion and proliferation such as PCNA, AgNOR, EGFR, cyclin D1, p53, and p21 and stimulating programmed malignant cell death without affecting noncancerous cells. Here, CCND1 is linked to neoplasm.